Details of the Drug

General Information of Drug (ID: DMU65NK)

Drug Name

Mycophenolic acid

Synonyms

Acide mycophenolique; Acide mycophenolique [INN-French]; Acido micofenolico; Acido micofenolico [INN-Spanish]; Acidum mycoph; Acidum mycophenolicum; CCRIS 5565; Lilly-68618; Ly 68618; Melbex; Micofenolico acido; Micofenolico acido [Spanish]; Mycophenolate; Mycophenolsaeure; Myfortic; NSC 129185; NSC-129185; UNII-HU9DX48N0T

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]
Middle East Respiratory Syndrome (MERS)	1D64	Investigative	[3]

Therapeutic Class

Antiviral Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

320.3

Topological Polar Surface Area (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.33 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 9.7 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 64.2163 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.77 L/kg [5]

Chemical Identifiers

Formula: C17H20O6
IUPAC Name: (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
Canonical SMILES: CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\\C)/CCC(=O)O)O
InChI: InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChIKey: HPNSFSBZBAHARI-RUDMXATFSA-N

Cross-matching ID

PubChem CID: 446541
ChEBI ID: CHEBI:168396
CAS Number: 24280-93-1
DrugBank ID: DB01024
TTD ID: D0Z8EV
ACDINA ID: D00450

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
MERS-CoV papain-like proteinase (PL-PRO)	TTYJOLE	R1AB_CVEMC (854-2740)	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mycophenolic acid (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Moderate	Decreased absorption of Mycophenolic acid due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[10]
Clindamycin	DM15HL8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Clindamycin.	Acne vulgaris [ED80]	[11]
Cefuroxime	DMSIMD8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefuroxime.	Acute bronchitis [CA42]	[11]
Paromomycin	DM1AGXN	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Paromomycin.	Amoebiasis [1A36]	[11]
Cefamandole	DMNEXZF	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefamandole.	Anaerobic bacterial infection [1A00-1A09]	[11]
Aminophylline	DML2NIB	Minor	Increased plasma concentration of Mycophenolic acid and Aminophylline due to competitive binding of plasma proteins.	Asthma [CA23]	[11]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Roflumilast.	Asthma [CA23]	[12]
Cefotetan	DM07TX3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefotetan.	Bacterial infection [1A00-1C4Z]	[11]
Ofloxacin	DM0VQN3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Oritavancin	DM28D05	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Oritavancin.	Bacterial infection [1A00-1C4Z]	[11]
Kanamycin	DM2DMPO	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Kanamycin.	Bacterial infection [1A00-1C4Z]	[11]
Ceftizoxime	DM3VOGS	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftizoxime.	Bacterial infection [1A00-1C4Z]	[11]
Dalfopristin	DM4LTKV	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalfopristin.	Bacterial infection [1A00-1C4Z]	[11]
Clarithromycin	DM4M1SG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[11]
Ticarcillin	DM4ME02	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ticarcillin.	Bacterial infection [1A00-1C4Z]	[11]
Cefoperazone	DM53PV8	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoperazone.	Bacterial infection [1A00-1C4Z]	[11]
Cefprozil	DM7DSYP	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefprozil.	Bacterial infection [1A00-1C4Z]	[11]
Sparfloxacin	DMB4HCT	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Ceftriaxone	DMCEW64	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftriaxone.	Bacterial infection [1A00-1C4Z]	[11]
Streptomycin	DME1LQN	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Streptomycin.	Bacterial infection [1A00-1C4Z]	[11]
Dalbavancin	DMGMNH3	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Dalbavancin.	Bacterial infection [1A00-1C4Z]	[11]
Gemifloxacin	DMHT34O	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Cefepime	DMHVWIK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefepime.	Bacterial infection [1A00-1C4Z]	[11]
Imipenem	DMI9FBP	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Imipenem.	Bacterial infection [1A00-1C4Z]	[11]
Meticillin	DMIKHN0	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Meticillin.	Bacterial infection [1A00-1C4Z]	[11]
Norfloxacin	DMIZ6W2	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[11]
ABT-492	DMJFD2I	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[11]
Cefpodoxime	DMJUNY5	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[11]
Cefadroxil	DMMC345	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefadroxil.	Bacterial infection [1A00-1C4Z]	[11]
Bacampicillin	DMP54C7	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[11]
Cefazolin	DMPDYFR	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefazolin.	Bacterial infection [1A00-1C4Z]	[11]
Novobiocin	DMRFWGK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Novobiocin.	Bacterial infection [1A00-1C4Z]	[11]
Levofloxacin	DMS60RB	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[11]
Cefditoren	DMSUVM1	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[11]
Cefonicid	DMTX2BH	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefonicid.	Bacterial infection [1A00-1C4Z]	[11]
Cefradine	DMUNSWV	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefradine.	Bacterial infection [1A00-1C4Z]	[11]
Cloxacillin	DMUTL7O	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cloxacillin.	Bacterial infection [1A00-1C4Z]	[11]
Amoxicillin	DMUYNEI	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Amoxicillin.	Bacterial infection [1A00-1C4Z]	[11]
Troleandomycin	DMUZNIG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[11]
Cefoxitin	DMYTXVR	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cefoxitin.	Bacterial infection [1A00-1C4Z]	[11]
Ceftibuten	DMWV2AG	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Ceftibuten.	Bronchitis [CA20]	[11]
Oxtriphylline	DMLHSE3	Minor	Increased plasma concentration of Mycophenolic acid and Oxtriphylline due to competitive binding of plasma proteins.	Cough [MD12]	[11]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Mycophenolic acid due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[10]
Benzylpenicillin	DMS9503	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Benzylpenicillin.	Discovery agent [N.A.]	[11]
Fosphenytoin	DMOX3LB	Minor	Increased plasma concentration of Mycophenolic acid and Fosphenytoin due to competitive binding of plasma proteins.	Epilepsy/seizure [8A61-8A6Z]	[11]
Lincomycin	DMVTHER	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Lincomycin.	Gram-positive bacterial infection [1B74-1F40]	[11]
Rifampin	DMA8J1G	Major	Increased metabolism of Mycophenolic acid caused by Rifampin mediated induction of UGT.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Mycophenolic acid and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[13]
TP-434	DM5A31S	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by TP-434.	Infectious gastroenteritis/colitis [1A40]	[11]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Mycophenolic acid and Denosumab.	Low bone mass disorder [FB83]	[14]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Mycophenolic acid caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[15]
Sulphadoxine	DMZI2UF	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Sulphadoxine.	Malaria [1F40-1F45]	[11]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Mycophenolic acid due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[16]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Tecfidera.	Multiple sclerosis [8A40]	[17]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Fingolimod.	Multiple sclerosis [8A40]	[18]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Ocrelizumab.	Multiple sclerosis [8A40]	[19]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Ozanimod.	Multiple sclerosis [8A40]	[12]
Gatifloxacin	DMSL679	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[11]
Colistimethate	DMZ9BMU	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Colistimethate.	Respiratory infection [CA07-CA4Z]	[11]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Canakinumab.	Rheumatoid arthritis [FA20]	[20]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Mycophenolic acid and Rilonacept.	Rheumatoid arthritis [FA20]	[20]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Mycophenolic acid and Golimumab.	Rheumatoid arthritis [FA20]	[21]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Mycophenolic acid and Leflunomide.	Rheumatoid arthritis [FA20]	[13]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Mycophenolic acid when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[22]
Cephapirin	DMV2JNY	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Cephapirin.	Sepsis [1G40-1G41]	[11]
Tedizolid	DMG2SKR	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Tedizolid.	Skin and skin-structure infection [1F28-1G0Z]	[11]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Mycophenolic acid caused by Pitolisant mediated induction of UGT.	Somnolence [MG42]	[12]
Doripenem	DM9UCJK	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Doripenem.	Urinary tract infection [GC08]	[11]
Plazomicin	DMKMBES	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Plazomicin.	Urinary tract infection [GC08]	[11]
Secnidazole	DMJ18YL	Moderate	Altered absorption of Mycophenolic acid due to GI flora changes caused by Secnidazole.	Vaginal discharge [MF3A]	[11]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Dextrin	E00359	62698	Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Mycophenolic acid 360 mg tablet	360 mg	Delayed Release Oral Tablet	Oral
Mycophenolic acid 180 mg tablet	180 mg	Delayed Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence. Ecancermedicalscience. 2020 Mar 27;14:1022.
3	SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
8	Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16.
9	Identification and Design of Novel Small Molecule Inhibitors Against MERS-CoV Papain-Like Protease via High-Throughput Screening and Molecular Modeling Bioorg Med Chem. 2019 May 15;27(10):1981-1989.
10	Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
11	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
12	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
13	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
14	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Canadian Pharmacists Association.
17	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
18	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
19	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
20	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
21	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
22	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]